Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 + Docetaxel in 2L NSCLC
NCT05943795Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoints: Overall Survival and Progression-Free Survival. Started Jul 2023; status: active, not recruiting.
02
Drugs
izalontamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05943795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943795.